Recombinant factor VIIa holds a great deal of promise as a hemostatic agent in many clinical settings; however, more large, randomized, controlled trials are needed to evaluate both the safety and efficacy of this apparently effective hemostatic agent, particularly in view of its cost. Cost-effectiveness studies are only in the planning stage for rFVIIa as of yet. To become cost-effective, dosing of rFVIIa should avoid costly returns in the operating room, shorten stays in the ICU, and prevent the need to give an additional 10 units of blood.
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine